Immune Deficiency Foundation Receives 167K Grant from FFF Enterprises to Launch National Education and Advocacy Program

August 18, 2005 Media Release

TOWSON, MD. and TEMECULA, Calif. - The Immune Deficiency Foundation (IDF), the nation's leading nonprofit patient organization for primary immune deficiency diseases, and FFF Enterprises Inc., the largest U.S. distributor of immune globulin products (IVIG), announced today that FFF has awarded a $167,000 grant to IDF.

The grant will be used to help fund the creation and management of a nationwide, grassroots campaign to educate legislators and public agencies about the impacts of public policy and funding decisions on the quality of care for people with primary immune deficiencies.

"FFF is a long-time supporter of IDF," explained Marcia Boyle, IDF board president, "and they have graciously agreed to restructure their $1 million, 5-year endowment pledge to accommodate this year's urgent need to develop and mobilize a network of volunteer advocates. Our community volunteers are the most effective educators about immune deficiency issues, because they are living with the consequences of public policies on a daily basis. Immune globulin is essentially their lifeblood, and today many of them are struggling to maintain access to this lifesaving therapy."

IDF's education and advocacy programs will be managed by the organization's staff members and implemented at the local and state levels by volunteers. Funding for the program will also support an advocacy coalition of patients, physicians and industry stakeholders, with the purpose of educating legislators and public agencies.

"Medicare reimbursement for IVIG and marketplace conditions are converging right now to have a terrible impact on the quality of care for many patients with immune deficiencies," said Patrick M. Schmidt, president and CEO of FFF. "IDF's goal, to help these patients tell their stories directly to those who most need to hear them, is probably the most powerful way to bring about a solution. FFF is honored to be able to support this effort, and we encourage everyone in the industry to join us in supporting it."

FFF's unique distribution business model has institutionalized Guaranteed Channel Integrity™, which reflects the company's commitment to purchase only from manufacturers and ship only to healthcare providers - one clear line with no gray in between. This protects products from secondary and gray markets, and enhances patient safety.

To make a contribution and for more information, contact IDF's Marcia Boyle at 800-296-4433.

About the Immune Deficiency Foundation
The Immune Deficiency Foundation (IDF) is the national nonprofit health organization dedicated to improving the diagnosis and treatment of primary immune deficiency diseases through research and education. There are as many as 50,000 people in the United States who have a primary immune deficiency disease. These individuals often find it difficult to receive specialized healthcare, proper diagnosis and treatment. Individuals affected by primary immune deficiency diseases also experience difficulties financing their healthcare, finding educational materials on the disease, and locating others with whom to share their experiences. The goal of IDF is to help individuals overcome these difficulties and live a healthy and productive life.

About FFF Enterprises
FFF Enterprises was founded in 1988 and has since grown into a multidimensional healthcare company, delivering innovative solutions in biopharmaceutical management and distribution, health information management and consumer healthcare services. FFF is now the nation's largest supplier of human plasma products and vaccines, and also distributes other biopharmaceuticals and clinical trial drugs. Customers of FFF's four divisions include members of the leading U.S. acute care and non-acute care group purchasing organizations, pharmaceutical manufacturers, biotech companies, contract research organizations, managed healthcare and consumers. FFF's unique distribution business model has institutionalized Guaranteed Channel Integrity, which reflects the company's commitment to purchase only from manufacturers and ship only to healthcare providers - one clear line with no gray in between. This protects products from secondary and gray markets, and improves patient safety.